Dexamethasone as a probe for CYP3A4 metabolism: Evidence of gender effect

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 2, 2007, Pages 305-308

  Puisset, F ^a   Chatelut, E ^a   Sparreboom, A ^b   Delord, J P ^a   Berchery, D ^a   Lochon, I ^a   Lafont, T ^a   Roche H ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cytochrome P450 3A4 5; Dexamethasone; Docetaxel; Gender; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; OROSOMUCOID; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; QUALIMED; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; EQUILIBRIUM DIALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER METASTASIS; MALE; MICRODIALYSIS; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SEX FACTORS; TAXOIDS;

EID: 34248385330     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0385-4     Document Type: Article

References (12)

1. Acharya MR, Baker SD, Verweij J, Figg WD, Sparreboom A (2004) Determination of fraction unbound docetaxel using microequilibrium dialysis. Anal Biochem 331:192-194
2. Baille P, Bruno R, Schellens JH, Webster LK, Millward M, Verweij J, Montay G (1997) Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 3:1535-1538
3. Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A (2005) Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther 77:43-43
4. Baker SD, Scher HI, Li J, Beekman KW, Stewart J, Collins C, Sinibaldi VJ, Walczack J, Pili R, Carducci MA (2005) Effect of androgen-ablation and hormonal cycling on docetaxel clearance in patients with metastatic prostate cancer. Proc ASCO 23 (abstr 4608)
5. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8:195-222
6. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ (1996) Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 277:105-112
7. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S (2000) CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28:1121-1127
8. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
9. Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azéma J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roché H (2004) Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 54:265-272
10. Puisset F, Dalenc F, Chatelut E, Cresteil T, Lochon I, Tisnes P, Roché (2005) Dexamethasone as a probe for vinorelbine clearance. Br J Clin Pharmaco 60:45-53
11. Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14:147-151
12. Vergniol JC, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278